Low dose ketamine increases prepulse inhibition in healthy men

Neuropharmacology

Volumn 44, Issue 6, 2003, Pages 729-737

  Abel, Kathryn M ^a   Allin, Matthew P G ^b   Hemsley, David R ^b   Geyer, Mark A ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ketamine; NMDA antagonists; Prepulse inhibition; Psychosis; Schizophrenia; Startle reflex

Indexed keywords

KETAMINE;

ACOUSTIC REFLEX; ADULT; ARTICLE; BEHAVIOR; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISORIENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HABITUATION; HUMAN; LATENT PERIOD; LOW DRUG DOSE; MALE; NEGATIVE SYNDROME; NORMAL HUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; STARTLE REFLEX; VOLUNTEER;

EID: 0037401922     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(03)00073-X     Document Type: Article

References (72)

1. Abduljawad K.A., Langley R.W., Bradshaw C.M., Szabadi E. Effects of bromocriptine and haloperidol on prepulse inhibition of the acoustic startle response in man. Journal of Psychopharmacology. 12:1998;239-245.
2. Abel K.M., Waikar P.B., Hemsley D.R., Geyer M.A. Repeated testing of PPI and habituation of the startle reflex: a study in healthy human controls. Journal of Psychopharmacology. 12:1998;330-337.
3. Abel K.M., Allin M.A., Geyer M.A. The effects of low dose ketamine on sensorimotor gating, cognitive performance and perception in healthy men. Journal of Psychopharmacology. 14:2000;A55.
4. Adler C.M., Goldberg T.E., Malhotra A.K., Pickar D., Breier A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biological Psychiatry. 43:1998;811-816.
5. Bakker C.B., Amini F.B. Observations on the psychotomimetic effects of sernyl. Comparative Psychology. 2:1961;269-280.
6. Bolino F., Di Michele V., Di Cicco L., Manna V., Daneluzzo E., Casacchia M. Sensorimotor gating and habituation evoked by electrocutaneous stimulation in schizophrenia. Biological Psychiatry. 36:1994;669-670.
7. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia: human and animal model studies. Archives of General Psychiatry. 47:1990;181-188.
8. Braff D.L., Stone C., Callaway E., Geyer M.A., Glick I., Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology. 15:1978;339-343.
9. Braff D.L., Grillon C., Geyer M.A. Gating and habituation of the startle reflex in schizophrenic patients. Archives of General Psychiatry. 49:1992;206-215.
10. Braff D.L., Swerdlow N.R., Geyer M.A. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. American Journal of Psychiatry. 156:1999;596-602.
11. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition (PPI) of startle: Normal subjects, patient groups, and pharmacological studies. Psychopharmacology. 156:2001;234-258.
12. Breier A., Malhotra A.K., Pinals D.A., Weisenfeld N.I., Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. American Journal of Psychiatry. 154:1997;805-811.
13. Bremner J.D., Krystal J.H., Putnam F.W., Southwick S.M., Marmar C., Charney D.S., Mazure C.M., et al. Measurement of dissociative states with the clinician administered dissociative states scale. Journal of Traumatic Stress. 11:1991;25-136.
14. Byrd L.D., Standish L.J., Howell L.L. Behavioural effects of phencyclidine and ketamine alone and in combination with other drugs. European Journal of Pharmacology. 144:1987;331-341.
15. Cadenhead K.S., Carasso B.S., Swerdlow N.R., Geyer M.A., Braff D. Prepulse inhibition and habituation of the startle response are stable neurobiological measures in a normal male population. Biological Psychiatry. 45:1999;60-364.
16. Carlsson M., Carlsson A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophrenia Bulletin. 16:1990;425-432.
17. Carlsson A., Hanssen L.O., Waters N., Carlsson M.L. A glutamatergic deficiency model of schizophrenia. British Journal of Psychiatry. 174:(suppl. 37):1999;2-7.
18. Castellanos F.X., Fine E.J., Kaysen D., Marsh W.L. Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biological Psychiatry. 39:1996;33-41.
19. Cohen M.L., Chan S.L., Bhargava H.N., Trevor A.J. Inhibition of mammalian brain acetylcholinesterase by ketamine. Biochemical Pharmacology. 23:1974;1647-1652.
20. Davies B.M., Beech H.R. The effect of 1-arylcyclohexylamine (sernyl) on 12 normal volunteers. Journal of Mental Science. 106:1960;912-924.
21. Davis M., Walker D.L., Lee Y. Neurophysiology and neuropharmacology of startle and its affective modification. Dawson M.E., Schell A.M., et al. Startle modification: Implications for neuroscience, cognitive science, and clinical science. 1999;114-133 Cambridge University Press, New York.
22. Dawson M.E., Schell A.M., Hazlett E.A., Nuechterlein K.H., Filion D.L. On the clinical and cognitive meaning of impaired sensorimotor gating in schizophrenia. Psychiatry Research. 96:2000;187-197.
23. Della Casa V., Hoffer I., Weiner I., Feldon J. The effects of smoking on acoustic prepulse inhibition in healthy men and women. Psychopharmacology. 137:1998;362-368.
24. Duncan E.J., Madonick S.H., Parwani A., Angrist B., Rajan R., Chakravorty S., Efferen T., Szilagyi S., Stephanides M., Chappel P.B., Gonzenbach S., Ko G.N., Rotrosen J.P. Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology. 25:2001;72-83.
25. Erard R., Luisiada O.V., Peele R. The PCP psychosis: prolonged intoxication or drug precipitated functional illness? Journal of Psychedelic Drugs. 12:1980;235-245.
26. Geyer M.A., Swerdlow N.R., Mansbach R.S., Braff D.L. Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Research Bulletin. 25:1990;485-498.
27. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology. 156:2001;117-154.
28. Ghoneim M.M., Hinrichs J.V., Mewaldt S.P., Petersen R.C. Ketamine: behavioral effects of subanesthetic doses. Journal of Clinical Psychopharmacology. 5:1985;70-77.
29. Gouzoulis-Mayfrank E., Heekeren K., Thelen B., Lindenblatt B., Kovar K.A., Sass H., Geyer M.A. Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behavioural Pharmacology. 9:1998;561-566.
30. Graham F. The more or less startling effects of weak prestimuli. Psychophysiology. 12:1975;238-248.
31. Grillon C., Ameli R., Charney D.S., Krystal J.H., Braff D.L. Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biological Psychiatry. 32:1992;843-939.
32. Hansen G., Jensen S.B., Chandresh L., Hilden T. The psychotropic effect of ketamine. Journal of Psychoactive Drugs. 20:1988;419-425.
33. Harborne G.C., Watson F.L., Healy D.T., Groves L. The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers. Journal of Psychopharmacology. 10:(2):1996;134-140.
34. Hazlett E.A., Buchsbaum M.S., Haznedar M., Mehmet, Singer M.B., Germans M.K., Schnur D.B., Jimenez E.A., Buchsbaum B.R., Troyer B.T. Prefrontal cortex glucose metabolism and startle eyeblink modification abnormalities in unmedicated schizophrenia patients. Psychophysiology. 35:1998;186-198.
35. Hedlund J.L., Vieweg B.W. The Brief Psychiatric Rating Scale (BPRS): a comprehensive review. Journal of Operating Psychology. 11:1980;48-64.
36. Hustveit O., Maurset A., Oye I. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacology and Toxicology. 7:1995;355-359.
37. Hutchison K.E., Swift R. Effect of D-amphetamine on prepulse inhibition of the startle reflex in humans. Psychopharmacology. 143:1999;394-400.
38. Javitt D.C., Lindsley R.W. Effects of phencyclidine on prepulse inhibition of acoustic startle response in the macaque. Psychopharmacology. 156:2001;165-168.
39. Javitt D., Zukin S. Recent advances in the phenylcyclidine model of schizophrenia. American Journal of Psychiatry. 148:1991;1301-1308.
40. Johnson J.D. A mechanism to inhibit input activation and its dysfunction in schizophrenia. British Journal of Psychiatry. 146:1985;429-435.
41. Karper L.P., Grillon C., Morrissey K., Abi-Saab D., Morgan C.A. III, Charney D.S., Krystal J.H. The effect of ketamine on the acoustic startle response. Society for Neuroscience Abstracts. 20:1994;482.
42. Koch M., Schnitzler H.U. The acoustic startle response in rats - circuits mediating evocation, inhibition and potentiation. Behavioural Brain Research. 89:1997;35-49.
43. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanaesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans. Archives of General Psychiatry. 51:1994;199-214.
44. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanaesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
45. Liddle P.F. The symptoms of chronic schizophrenia. A re-examination of the positiveengative dichotomy. British Journal of Psychiatry. 15:1987;145-151.
46. Luby E.D., Gottlieb J.S., Cohen B.D., Rosenbaum G., Domino E.F. Model psychosis and schizophrenia. American Journal of Psychiatry. 119:1962;61-65.
47. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 14:1996;301-307.
48. Mansbach R.S., Geyer M.A. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology. 2:1989;299-308.
49. Mansbach R.S., Geyer M.A. Parametric determinants in prestimulus modification of acoustic startle: interaction with ketamine. Psychopharmacology. 105:1991;162-168.
50. Mansbach R.S., Geyer M.A., Braff D.L. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology. 94:1988;507-514.
51. Maurset A., Skoglund L.A., Hustveit O., Oye I. Comparison of ketamine and pethidine in experimental and postoperative pain. Pain. 36:1989;37-41.
52. Mirkin A.M. Bimodal electrodermal activity in schizophrenia. British Journal of Clinical Psychology. 24:1985;131-132.
53. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal of Neuroscience. 17:1997;2921-2927.
54. Moretti R.J., Hassan S.Z., Goodman L.I., Meltzer H.Y. Comparison of ketamine and thiopental in healthy volunteers: effects on mental status, mood and personality. Anesthesia and Analgesics. 63:1984;1087-1096.
55. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychology Reports. 10:1962;799-812.
56. Oye N., Paulsen O., Maurset A. Effects of ketamine sensory perception: evidence for a role of N-methyl-D-aspartate receptors. Journal of Pharmacology and Experimental Therapy. 260:1992;1209-1213.
57. Perry W., Braff D.L. Information-processing deficits and thought disorder in schizophrenia. American Journal of Psychiatry. 151:(363-36):1994;7.
58. Perry W., Geyer M.A., Braff D.L. Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients. Archives of General Psychiatry. 56:1999;277-281.
59. Rascle C., Mazas O., Vaiva G., Journant M., Raybois O., Goudemand M., Thomas P. Clinical features of latent inhibition in schizophrenia. Schizophrenia Research. 51:2001;149-161.
60. Schwarzkopf S.B., McCoy L., Smith D.A., Boutros N.N. Test-retest reliability of prepulse inhibition of the acoustic startle response. Biological Psychiatry. 34:1993;896-900.
61. Smith D.J., Azzaro A.J., Zalvida S.B., Palmer S., Lee H.S. Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacology. 20:1981;391-396.
62. Swerdlow N.R., Geyer M.A. Neurophysiology and neuropharmacology of short lead interval startle modification. Dawson M.E., Schell A.M., et al. Startle modification: Implications for neuroscience, cognitive science, and clinical science. 1999;114-133 Cambridge University Press, New York.
63. Swerdlow N.R., Benbow C.H., Zisook S., Geyer M.A., Braff D.L. A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biological Psychiatry. 108:1993;189-195.
64. Swerdlow N.R., Paulsen J., Braff D.L., Butters N., Geyer M.A., Swenson M.R. Impaired prepulse inhibition of acoustic and tactile startle in patients with Huntington's disease. Journal of Neurological and Neurosurgical Psychology. 58:1995;192-200.
65. Swerdlow N.R., Braff D.L., Geyer M.A. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behavioural Pharmacology. 11:2000;185-204.
66. Swerdlow N.R., Geyer M.A., Braff D.L. Neural circuitry of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology. 156:2001;194-215.
67. Van Berckel B.N.M., Oranje B., van Ree J.M., Verbaten M.N., Kahn R.S. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology. 137:1998;271-281.
68. Vollenweider F.X., Leenders K.L., Scharfetter C., Antonini A., Maguire P., Missimer J. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [-super(18)F]fluorodeoxyglucose (FDG). European Journal of Neuropsychopharmacology. 7:(1):1997;9-24.
69. Vollenweider F.X., Leenders K.L., Oye I., Hell D., Angst J. Differential psychopathology and patterns of cerebral glucose utilization produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). European Journal of Neuropsychopharmacology. 7:1997;25-38.
70. Vollenweider F.X., Remensberger S., Hell D., Geyer M.A. Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology. 143:1999;365-372.
71. Vollenweider F.X., Umbricht D., Geyer M.A., Hell D. Effects of NMDA antagonists and 5-HT2a antagonists on prepulse inhibition in human volunteers. Schizophrenia Research. 41:(1):2000;147.
72. Weike A.I., Bauer U., Hamm A.O. Effective neuroleptic medication removes deficits of prepulse inhibition. Biological Psychiatry. 47:2000;61-70.